Scott Randal W. 4
4 · BridgeBio Pharma, Inc. · Filed Jun 5, 2024
Insider Transaction Report
Form 4
Scott Randal W.
Director
Transactions
- Sale
Common Stock
2024-06-03$28.68/sh−800$22,948→ 5,700 total(indirect: By LLC) - Sale
Common Stock
2024-06-03$29.48/sh−200$5,895→ 5,500 total(indirect: By LLC) - Sale
Common Stock
2024-06-04$31.30/sh−1,500$46,950→ 4,000 total(indirect: By LLC)
Holdings
- 5,000
Common Stock
Footnotes (3)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by Thinking Bench Capital LLC on June 6, 2023.
- [F2]Represents the weighted average sale price of the shares sold ranging from $28.31 to $29.24 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F3]Represents the weighted average sale price of the shares sold ranging from $29.44 to $29.55 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.